

Denosumab (Prolia or Biosimilar)

Infusion Office Preference:			
PATIENT INFORMATION			
Date: Patient Name:		DOB:	
□ NKDA Allergies:	Weight (lbs / kg):	Height:	
Patient Status: ☐ New to Therapy ☐ Continuing	Therapy - Last Treatment Date:	Next Due Date:	
PROVIDER INFORMATION			
Office Contact Name:	Office Email:		
Prescribing Providers Name:	Provider NPI:		
Office Address:	City:	State: Zip:	
Office Phone Number:	Office Fax Number:		
DIAGNOSIS AND ICD 10 CODE			
☐ Osteoporosis in women or men at high risk of	developing fracture ICD-10 Code:	M81.0	
☐ Other Diagnosis:	ICD-10 Code:		
REQUIRED DOCUMENTATION/Testing			
 □ This signed order form by the provider □ Patient demographics AND insurance info □ Clinical/Progress notes supporting primary dx 	☐ DEXA scan results and	☐ Calcium drawn and noted to be WNL and results sent☐ DEXA scan results and/or FRAX score	
List Tried & Failed Therapies 1)	2)		
MEDICATION ORDERS			
■ Denosumab 60mg SubQ every 6 months (Pharmacy to dispense based off of product availability) □ Dispense as written Prolia (no substitutions)			
SPECIAL INSTRUCTIONS			
* Referring physician is responsible for monitoring and reviewing serum Calcium level prior to dose of Prolia. ** Clinical monitoring of calcium, phosphorus, and magnesium is highly recommended in patients with severe renal impairment Adequately supplement all patients with Calcium and vitamin D.			
Provider Name (Print)	**Physician Signature:	Date:	

REFERRAL STATUS: \square New Referral \square Dose or Frequency Change \square Order Renewal